biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Some Thoughts in Summary

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 23, 2022 1:52pm

89 Views

Post# 35189995

RE:RE:RE:RE:RE:RE:Some Thoughts in Summary

"Lol, poof, Q123 starts in a week. With the financings you say that Midatech says that they would have enough money for another 2 to 3 quarters."

No. I'm saying that it is inconcievable that happened. There is high confidence significant cash is near. If there isn't they are in the same spot that led to this catastrophic dilution. Biodexa with Ladenberg Thalmann have defined a path out of this treacherous time for biotech. Cash is king. Armistice Capital sees a path.

prophetoffactz wrote: "Management estimates that the current cash balance (c £3.6m) will provide operational cash runway until Q123, which could extend to Q423 on successful conclusion of the fund-raise and acquisition." Edison Group

It is very dumb to put a deal together like this and only provide it with a cash runway to Q4 2023. With one placee alone they raised US$10 million upfront. They should have been able to find more than one firm interested in this deal. Armisitice Capital is a very strong fund it is not like Ladenberg Thalmann was scraping the bottom of the barrel to raise funds. That only this amount of cash is being raised appears to speak to Biodexa's high confidence in additional cash in the near term potenially through deals(eg. J&J, Neuremedy, cancer, etc.), deal monitization, or the exercise of the US$10 million warrants by Armistice Capital. There would appear to be more money expected near term that can secure a cash runway in a very difficult time for biotech and to reach hard data milestones on the lead clinical assets.